Foreign Exchange Rates Said To Bode Well For Chinese Pharmas
This article was originally published in PharmAsia News
Chinese drug makers can expect to benefit by a foreign exchange rate that makes the yuan stronger against the American dollar and other currencies. The situation is expected to lead to greater foreign investments in China's industry and give drug makers greater domestic purchasing power. At the same time, foreign competitors face greater operating costs in China, leading them to expect a greater contribution from alliances with other Chinese firms. The estimates come from Synthetic Organic Chemical Manufacturers Association, a global group for chemical companies. (Click here for more
You may also be interested in...
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.